Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Enterprise Value (2017 - 2025)

Serina Therapeutics' Enterprise Value history spans 9 years, with the latest figure at -$8.8 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 169.39% year-over-year to -$8.8 million; the TTM value through Sep 2025 reached -$8.8 million, down 169.39%, while the annual FY2024 figure was -$3.8 million, 113.22% down from the prior year.
  • Enterprise Value for Q3 2025 was -$8.8 million at Serina Therapeutics, down from -$6.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $28.8 million in Q4 2023 and bottomed at -$8.8 million in Q3 2025.
  • The 5-year median for Enterprise Value is -$742000.0 (2021), against an average of -$984263.2.
  • The largest annual shift saw Enterprise Value surged 4194.59% in 2023 before it tumbled 2885.32% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$643000.0 in 2021, then dropped by 9.33% to -$703000.0 in 2022, then soared by 4194.59% to $28.8 million in 2023, then tumbled by 113.22% to -$3.8 million in 2024, then plummeted by 130.38% to -$8.8 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Enterprise Value are -$8.8 million (Q3 2025), -$6.2 million (Q2 2025), and -$4.4 million (Q1 2025).